权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Angiogenin in ALS Pathobiology and Therapy

ALS 病理学和治疗中的血管生成素

基本信息

批准号：
7783075
负责人：
GUO-FU HU
金额：
$ 9.68万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-03-15 至 2010-06-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7783075
关键词：
Actins Adult Adverse effects Amyotrophic Lateral Sclerosis Animal Model Animals Blood Blood Vessels Body Weight decreased Candidate Disease Gene Cells Cessation of life Clinical Research Code Data Defect Degenerative Disorder Development Dose Drug Kinetics Endothelial Cells Functional disorder Genes Goals Human Hypoxia Intraperitoneal Injections Knockout Mice Maximum Tolerated Dose Mediating Messenger RNA Missense Mutation Motor Motor Neurons Mus Muscle Neuraxis Neurites Neurons Onset of illness Outcome Study Partner in relationship Pathogenesis Pathology Patients Phenotype Physiology Play Proteins Publishing Regimen Reporting Ribonucleases Role Spinal Cord Staging Stress Symptoms Tamoxifen Therapeutic Time Tissues Toxic effect Transgenic Mice Transgenic Organisms Variant Work angiogenin clinical application effective therapy fetal improved in vitro activity intraperitoneal loss of function loss of function mutation motor neuron degeneration motor neuron function mutant neurotoxicity overexpression pre-clinical prevent public health relevance transgene expression

项目摘要

DESCRIPTION (provided by applicant): The objective of this proposal is to elucidate the role of angiogenin in amyotrophic lateral sclerosis (ALS) pathobiology and to examine the therapeutic potential of angiogenin protein in ALS treatment. The hypothesis is that angiogenin plays a role in motor neuron function and that systemic treatment with angiogenin protein will prevent motor neuron degeneration and will improve the motor muscular function of ALS patients and prolong their survival. This hypothesis is formulated from published work that loss-of-function mutations of ANG occur in ALS patients and that angiogenin is strongly expressed in motor neurons of both fetal and adult human spinal cord. Our preliminary studies have shown that angiogenin expression is decreased in the spinal cord of human ALS patients and in that of SOD1G93A mice that develop ALS-like symptoms. Together with the report that WT angiogenin proteins prevent hypoxia-induced motor neuron death, a protective role of angiogenin against motor neuron degeneration in ALS patients can be expected. Moreover, we have shown that i.p.-administered angiogenin protein reaches the spinal cord and improves the motor muscular function of SOD1G93A mice and prolongs their survival by 4 weeks. We are going to 1) create conditional and inducible Ang1 knockout mice and characterize the role of angiogenin during development and in ALS pathology; 2) generate tissue- and time-specific ANG:SOD1G93A double transgenic mice and examine the effect of ANG overexpression on SOD1G93A-induced motor neuron toxicity; and 3) optimize the therapeutic activity of angiogenin protein in SOD1G93A mice. We expect that the outcome of this study will characterize the role of angiogenin in ALS pathogenesis and will elucidate the mechanism of neuron protective activity of angiogenin. We also expect to obtain an optimal dosing regimen, tolerability, toxicity, and pharmacokinetics of angiogenin in the treatment of SOD1G93A mice and to use these data to guide further preclinical and clinical studies. PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis is a devastating motor neuron degenerative disease without effective treatment. The goal of this proposal is to understand the role of angiogenin in motor neuron physiology and function, and to assess therapeutic activity of angiogenin in ALS treatment.

描述（由申请人提供）：本提案的目的是阐明血管生成素在肌萎缩侧索硬化症（ALS）病理生物学中的作用，并检查血管生成素蛋白在ALS治疗中的治疗潜力。假设血管生成素在运动神经元功能中起作用，全身用血管生成素蛋白治疗可防止运动神经元退行性变，改善ALS患者的运动肌肉功能，延长其生存期。这一假设是根据已发表的研究成果制定的，即ALS患者中发生ANG的功能丧失突变，血管生成素在胎儿和成人脊髓的运动神经元中都有强烈表达。我们的初步研究表明，血管生成素在人类ALS患者和出现ALS样症状的SOD1G93A小鼠脊髓中的表达降低。结合WT血管生成素蛋白预防缺氧诱导的运动神经元死亡的报道，可以预期血管生成素对ALS患者运动神经元变性的保护作用。此外，我们已经证明，ip给药血管生成素蛋白到达脊髓，改善SOD1G93A小鼠的运动肌肉功能，延长其生存4周。我们将1)创建条件和诱导Ang1敲除小鼠，并表征血管生成素在发育和ALS病理中的作用；2)生成组织特异性和时间特异性的ANG:SOD1G93A双转基因小鼠，并检测ANG过表达对SOD1G93A诱导的运动神经元毒性的影响；3)优化血管生成素蛋白对SOD1G93A小鼠的治疗活性。我们期望本研究的结果能够表征血管生成素在ALS发病机制中的作用，并阐明血管生成素对神经元保护作用的机制。我们还希望获得血管生成素治疗SOD1G93A小鼠的最佳给药方案、耐受性、毒性和药代动力学，并利用这些数据指导进一步的临床前和临床研究。